22157.jpg
Outlook on the TIL Therapies Global Market to 2035: by Target Indication, Key Players and Key Geographical Regions
01 févr. 2023 06h33 HE | Research and Markets
Dublin, Feb. 01, 2023 (GLOBE NEWSWIRE) -- The "Global TIL Therapies Market : Distribution by Target Indication, Key Players and Key Geographical Regions: Industry Trends and Global Forecasts,...
22157.jpg
Outlook on the Monkeypox Treatment Global Market to 2035 - Focus on Therapeutics, Vaccines and Diagnostic Kits
31 janv. 2023 10h38 HE | Research and Markets
Dublin, Jan. 31, 2023 (GLOBE NEWSWIRE) -- The "Monkeypox Treatment Market: Focus on Therapeutics, Vaccines and Diagnostic Kits: Distribution by Type of Product, Drug Developers, Drug Candidates,...
New Logo.png
Provectus Biopharmaceuticals Releases 2023 Stockholder Letter
09 janv. 2023 08h00 HE | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that it had issued a beginning-of-the-year letter for 2023 to the Company’s stockholders, which may be found...
22157.jpg
1 Day Fundamentals of Pharmacokinetics Seminar: The Processes that a Drug Undergoes After Administration
30 déc. 2022 05h03 HE | Research and Markets
Dublin, Dec. 30, 2022 (GLOBE NEWSWIRE) -- The "Full Day Virtual Seminar on Fundamentals of Pharmacokinetics" webinar has been added to ResearchAndMarkets.com's offering.Pharmacokinetics (PK) and...
22157.jpg
Insights on the Bioavailability Enhancement Technologies and Services Global Market to 2035 - Industry Trends and Forecasts
12 déc. 2022 08h18 HE | Research and Markets
Dublin, Dec. 12, 2022 (GLOBE NEWSWIRE) -- The "Bioavailability Enhancement Technologies and Services Market by Drug Class, BCS Classification, Bioavailability Enhancement Approach, Dosage Form and...
New Logo.png
Provectus Biopharmaceuticals Announces Decision to Not Undertake Reverse Split of Outstanding and Authorized Equities in 2022; Expects to Seek Same Stockholder Approval Again in 2023
12 déc. 2022 08h00 HE | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company’s Board of Directors (Board) has decided to not undertake the reverse stock split and...
22157.jpg
Cytotoxic Drugs and HPAPI Manufacturing Market Analysis Report 2022: New Research on 1 of the Most Powerful and Dynamic Sectors of the Pharmaceutical Industry - Industry Trends and Forecasts to 2035
07 déc. 2022 08h38 HE | Research and Markets
Dublin, Dec. 07, 2022 (GLOBE NEWSWIRE) -- The "Cytotoxic Drugs and HPAPI Manufacturing Market by Type of Product, Company Size, Scale of Operation, Type of Molecule, Type of Highly Potent Finished...
Synthetic Small Molecule API Market
Synthetic Small Molecule API Market Report 2022: High Demand for Generic Drugs Bolsters Sector
01 déc. 2022 07h38 HE | Research and Markets
Dublin, Dec. 01, 2022 (GLOBE NEWSWIRE) -- The "Synthetic Small Molecule API Market Share, Size, Trends, Industry Analysis Report, By Application; By Manufacturer; By Region; Segment Forecast,...
New Logo.png
Provectus Biopharmaceuticals Announces New Data from Combination Therapy Trial of Small Molecule Cancer Immunotherapy PV-10® and Keytruda® for First-Line Stage III Melanoma at Melanoma Bridge 2022
01 déc. 2022 07h00 HE | Provectus Biopharmaceuticals Inc.
50% CR and 83% ORR by RECIST 1.1 criteriaRapid CRs achieved within 15 to 27 weeksMedian PFS not reached during 2-year treatment interval; 83% PFS rate100% OS rate for CRs; ongoing after 18 to 36...
Global Recombinant Proteins Market
Recombinant Proteins Market Report 2022:Rising Government Funding and Increasing R&D Expenditure in Pharmaceutical and Biotechnology Companies Boosts Sector
30 nov. 2022 05h29 HE | Research and Markets
Dublin, Nov. 30, 2022 (GLOBE NEWSWIRE) -- The "Recombinant Proteins Market by Product (Growth Factors, Chemokines, Structural Proteins, Membrane Proteins), Application (Drug Discovery &...